MacNeil Adam, Sarr Abdoulaye Dieng, Sankalé Jean-Louis, Meloni Seema Thakore, Mboup Souleymane, Kanki Phyllis
Department of Immunology and Infectious Diseases, Harvard School of Public Health, 651 Huntington Ave., Boston, MA 02115, USA.
J Virol. 2007 May;81(10):5325-30. doi: 10.1128/JVI.02625-06. Epub 2007 Feb 28.
Studies have shown that human immunodeficiency virus type 2 (HIV-2) is less pathogenic than HIV-1, with a lower rate of disease progression. Similarly, plasma viral loads are lower in HIV-2 infection, suggesting that HIV-2 replication is restricted in vivo in comparison to that of HIV-1. However, to date, in vivo studies characterizing replication intermediates in the viral life cycle of HIV-2 have been limited. In order to test the hypothesis that HIV-2 has a lower replication rate in vivo than HIV-1 does, we quantified total viral DNA, integrated proviral DNA, cell-associated viral mRNA, and plasma viral loads in peripheral blood samples from groups of therapy-naïve HIV-1-infected (n = 21) and HIV-2-infected (n = 18) individuals from Dakar, Senegal, with CD4(+) T-cell counts of >200/microl. Consistent with our previous findings, total viral DNA loads were similar between HIV-1 and HIV-2 and plasma viral loads were higher among HIV-1-infected individuals. Proportions of DNA in the integrated form were also similar between these viruses. In contrast, levels of viral mRNA were lower in HIV-2 infection. Our study indicates that HIV-2 is able to establish a stable, integrated proviral infection in vivo, but that accumulation of viral mRNA is attenuated in HIV-2 infection relative to that in HIV-1 infection. The differences in viral mRNA are consistent with the differences in plasma viral loads between HIV-1 and HIV-2 and suggest that lower plasma viral loads, and possibly the attenuated pathogenesis of HIV-2, can be explained by lower rates of viral replication in vivo.
研究表明,2型人类免疫缺陷病毒(HIV-2)的致病性低于HIV-1,疾病进展率较低。同样,HIV-2感染时血浆病毒载量较低,这表明与HIV-1相比,HIV-2在体内的复制受到限制。然而,迄今为止,对HIV-2病毒生命周期中复制中间体进行特征描述的体内研究一直很有限。为了验证HIV-2在体内的复制率低于HIV-1这一假设,我们对来自塞内加尔达喀尔的初治HIV-1感染组(n = 21)和HIV-2感染组(n = 18)外周血样本中的总病毒DNA、整合前病毒DNA、细胞相关病毒mRNA和血浆病毒载量进行了定量,这些个体的CD4(+) T细胞计数>200/微升。与我们之前的研究结果一致,HIV-1和HIV-2之间的总病毒DNA载量相似,而HIV-1感染个体的血浆病毒载量更高。这些病毒之间整合形式的DNA比例也相似。相比之下,HIV-2感染时病毒mRNA水平较低。我们的研究表明,HIV-2能够在体内建立稳定的整合前病毒感染,但相对于HIV-1感染,HIV-2感染时病毒mRNA的积累减弱。病毒mRNA的差异与HIV-1和HIV-2之间血浆病毒载量的差异一致,表明较低的血浆病毒载量以及可能的HIV-2致病性减弱可以用体内较低的病毒复制率来解释。